Affiliation:
1. Dallas Diabetes and Endocrine Center Dallas, Texas
2. Veterans Affairs Medical Center Palo Alto/Livermore Division Livermore
3. Scripps Clinic La Jolla, California
4. Hoechst Marion Roussel Bridgewater, New Jersey
Abstract
OBJECTIVE
To compare the efficacy and safety of two daily doses of the new sulfonylurea, glimepiride (Amaryl), each as a once-daily dose or in two divided doses, in patients with NIDDM.
RESEARCH DESIGN AND METHODS
Of the previously treated NIDDM patients, 416 entered this multicenter randomized double-blind placebo-controlled fixed-dose study. After a 3-week placebo washout, patients received a 14-week course of placebo or glimepiride 8 mg q.d., 4 mg b.i.d., 16 mg q.d., or 8 mg b.i.d.
RESULTS
Fasting plasma glucose (FPG) and HbA1c values were similar at baseline in all treatment groups. The placebo group's FPG value increased from 13.0 mmol/l at baseline to 14.5 mmol/l at the last evaluation endpoint (P ≤ 0.001). In contrast, FPG values in the four glimepiride groups decreased from a range of 12.4–12.9 mmol/l at baseline to a range of 8.6–9.8 mmol/l at endpoint (P ≤ 0.001, within-group change from baseline; P ≤ 0.001, between-group change [vs. placebo] from baseline). Two-hour postprandial plasma glucose (PPG) findings were consistent with FPG findings. In the placebo group, the HbA1c value increased from 7.7% at baseline to 9.7% at endpoint (P ≤ 0.001), whereas HbA1c values for the glimepiride groups were 7.9–8.1% at baseline and 7.4–7.6% at endpoint (P ≤ 0.001, within-group change from baseline; P ≤ 0.001, between-group change from baseline). There were no meaningful differences in glycemic variables between daily doses of 8 and 16 mg or between once- and twice-daily dosing. Adverse events and laboratory data demonstrate that glimepiride has a favorable safety profile.
CONCLUSIONS
Glimepiride is an effective and well-tolerated oral glucose-lowering agent. The results of this study demonstrate maximum effectiveness can be achieved with 8 mg q.d. of glimepiride in NIDDM subjects.
Publisher
American Diabetes Association
Subject
Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine
Cited by
117 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献